Wockhardt exits its US generics business
[ad_1] Wockhardt Ltd is exiting its loss-making US generics business, as it focuses on its new antibiotics drug discovery and insulin portfolios. The drugmaker said on Friday that it has made a Chapter 7 filing for voluntary liquidation of its US subsidiaries Morton Grove Pharmaceuticals Inc. and Wockhardt USA LLC. The business has been incurring … Read more